Sermorelin was FDA approved, but it is no longer on the market. The original brand-name product, Geref, received its first FDA approval on December 28, 1990, and a second approval on September 26, 1997 for different dosage forms. The manufacturer, EMD Serono, voluntarily discontinued both products in 2008, and the FDA formally withdrew approval effective June 18, 2009. Today, sermorelin exists in a regulatory gray area: no FDA-approved version is commercially available, but compounding pharmacies still prepare and sell it by prescription.
Why Sermorelin Was Pulled From the Market
Sermorelin is a synthetic version of a hormone your body naturally produces to tell the pituitary gland to release growth hormone. Geref was originally marketed as an alternative to synthetic growth hormone injections for children who weren’t growing normally because their pituitary glands weren’t producing enough on their own.
The product simply couldn’t compete commercially with synthetic growth hormone, which was more established and widely prescribed. EMD Serono notified the FDA in mid-2008 that it was discontinuing both dosage forms. The FDA then moved Geref to the “Discontinued Drug Product List” in its Orange Book, which is the agency’s official catalog of approved medications.
This distinction matters: the FDA investigated and formally determined that Geref was not withdrawn for reasons of safety or effectiveness. It was a business decision by the manufacturer, not a safety recall. That determination, published in the Federal Register in March 2013, means sermorelin’s discontinuation carries no safety stigma in the eyes of the FDA.
How Sermorelin Is Still Available
Even though no FDA-approved version exists, sermorelin remains widely available through compounding pharmacies. These are pharmacies that custom-prepare medications, often from bulk raw ingredients, rather than dispensing mass-manufactured drugs. Under federal pharmacy compounding rules, they can legally prepare sermorelin with a valid prescription from a licensed provider.
As of 2026, sermorelin does not appear on the FDA’s list of bulk drug substances that present significant safety risks for compounding. This means the FDA has not flagged compounded sermorelin as particularly dangerous, though compounded medications in general don’t go through the same rigorous testing, manufacturing standards, and quality controls that FDA-approved drugs do. The potency, purity, and sterility of a compounded product depend heavily on the individual pharmacy preparing it.
What Sermorelin Does in the Body
Rather than replacing growth hormone directly, sermorelin works one step upstream. It mimics the natural signaling molecule (growth hormone-releasing hormone) that tells your pituitary gland to produce and release growth hormone on its own. This means the pituitary still controls how much growth hormone enters your bloodstream, which in theory keeps levels closer to a normal physiological range than direct growth hormone injections would.
This mechanism is why sermorelin has become popular in anti-aging and wellness clinics. Providers prescribe it off-label for adults experiencing symptoms associated with declining growth hormone levels, such as decreased energy, increased body fat, reduced muscle mass, and poor sleep quality. None of these adult uses were part of the original FDA-approved indication, which was limited to children with growth hormone deficiency.
Side Effects to Be Aware Of
Because sermorelin stimulates growth hormone production, its side effects overlap with those seen in growth hormone therapy more broadly. The most commonly reported issues include joint pain, muscle soreness, swelling in the hands or feet, headaches, and tingling or numbness in the skin. Injection site reactions like redness, itching, and pain are also common, since sermorelin is given as a subcutaneous injection.
Nausea and rash occur in a smaller percentage of users. Because growth hormone affects blood sugar regulation, people with diabetes or prediabetes should be cautious, as sermorelin can push glucose levels higher. It’s also not appropriate for anyone with a history of cancer, since growth hormone can theoretically promote cell growth.
How It Compares to Other Options
Sermorelin belongs to a class of drugs called growth hormone secretagogues, meaning they stimulate your body to secrete more growth hormone. Several similar compounds exist, but the regulatory landscape is narrow. Tesamorelin, a closely related peptide that also mimics growth hormone-releasing hormone, holds active FDA approval specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Other popular secretagogues like ibutamoren (MK-677) and various growth hormone-releasing peptides are not FDA approved at all and are also sourced primarily through compounding pharmacies or research chemical suppliers.
Synthetic growth hormone itself remains the most established FDA-approved option for diagnosed growth hormone deficiency in both children and adults. It’s a direct replacement rather than a stimulator, which means it bypasses the pituitary entirely. This makes it more predictable in terms of dosing but also carries a higher risk of pushing growth hormone levels above the normal range.
What This Means If You’re Considering Sermorelin
If a clinic or provider is offering you sermorelin, they’re prescribing a compounded version of a medication that once held FDA approval but no longer does. That’s not inherently dangerous, but it does mean the product you receive hasn’t been manufactured under the same oversight as a drug you’d pick up at a retail pharmacy. The quality depends on the compounding pharmacy, and there’s no standardized commercial product to compare it against.
You’re also likely being prescribed it for a use that was never formally evaluated and approved by the FDA. The original approval was for pediatric growth hormone deficiency, not for the anti-aging, body composition, or wellness purposes that dominate its current use. Clinical evidence supporting these off-label applications exists but is limited compared to what the FDA would require for a new drug approval. The peptide itself has a long track record, but the specific way it’s being used today in most clinics has not been through the full regulatory process.